phergain: chemo de-escalation using f-pet in her2 breast cancer
Published 4 years ago • 128 plays • Length 7:15Download video MP4
Download video MP3
Similar videos
-
0:54
treatment de-escalation in premenopausal patients with hr /her2- breast cancer and micro-metastasis
-
1:59
adapt: de-escalated neoadjuvant pertuzumab trastuzumab with or without paclitaxel in hr-/her2 ebc
-
0:54
neo-checkray: chemotherapy and sbrt with durvalumab and oleclumab in er /her2- breast cancer
-
1:01
future of breast cancer care: her2 therapies in earlier settings & de-escalation
-
1:40
precious: pertuzumab retreatment in patients with her breast cancer
-
0:58
enhertu therapy: a powerful new cancer treatment
-
4:14
phergain trial id's early breast cancer cases that benefit from dual her2 blockade without chemo
-
1:27
next steps in breast cancer: de-escalation & immunotherapy
-
1:38
compassher2-pcr: de-escalation of neoadjuvant chemotherapy for breast cancer
-
5:56
beyond chemotherapy: phergain clinical trial in her2 early breast cancer
-
4:29
pertuzumab, trastuzumab and cyclophosphamide in older patients with her2 breast cancer
-
3:50
herceptin (trastuzumab) for her2-positive breast and stomach cancer
-
3:08
rxponder: sparing chemotherapy in node-positive early-stage breast cancer
-
7:50
beyond chemotherapy: phergain clinical trial in her2 early breast cancer
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
5:49
breast cancer breakthroughs: advances in chemotherapy de-escalation
-
1:16
breast cancer breakthroughs highlights from asco 2023: phergain trial
-
4:52
3-year dfs in randomized trials of chemotherapy and her2-targeted therapy
-
3:46
outcomes from adapt-hr-/her2 evaluating dual her2 blockade